Virtual Library

Start Your Search

Pio Maniscalco

Author of

  • +

    P3.03 - Biology (Not CME Accredited Session) (ID 969)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
    • +

      P3.03-22 - IL-1β as a New Early Predictive Biomarker for Non-Small Cell Lung Cancers Outcome (ID 14184)

      12:00 - 13:30  |  Author(s): Pio Maniscalco

      • Abstract
      • Slides


      Lung cancer is the first cause of cancer mortality worldwide. Patients diagnosed with early stage disease (stage I) have been considered to have a reasonably favourable prognosis. Unfortunately, up to 40% early stage cases of all non-small cell lung cancers (NSCLCs) have a poor prognosis.

      Recent studies have suggested that combined modality treatment of NSCLC may improve survival in selected patients. One of the most critical questions in choosing the appropriate use of combined therapy is determining which patients might benefit from the more aggressive treatment.

      Recent data have enhanced the idea that inflammation is a critical component of tumour progression. It is now becoming clear that the tumour microenvironment is largely orchestrated by inflammatory cells and it is an indispensable participant in the carcinogenesis.

      In particular, IL-1b is a pleiotropic pro-inflammatory cytokine and its up-regulation is closely associated with various cancers. Chronic inflammation (sustained by overactivation of IL-1b system) is a crucial event in carcinogenesis and tumor progression and there is evidence that plasma IL-1b level is higher in patients with advanced cancers.

      Our goal is to determine whether IL-1b expression might be associated with NSCLCs patients’ clinical outcome.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      Patients diagnosed with lung cancer stage I and treated with potentially curative resection during 2012 were recruited for this study.

      Tissue samples (tumor masses including peri-tumoral stroma and lungs) were collected during surgery, embedded in paraffin and processed for immunohistochemistry (IHC). IHC was performed by ABC-peroxidase. Adjacent sections were incubated for 1 h at room temperature with monoclonal antibody against human IL-1b.

      4c3880bb027f159e801041b1021e88e8 Result

      In our randomized experiment 35 patients with NSCLC whose tumor was resected or biopsied were enrolled during 2012 and followed up for 5 years through 2017.

      Our preliminary results showed that patients with high levels of IL-1b in the peritumoral area, revealed by IHC, present a poor prognosis and a reduced overall survival.

      8eea62084ca7e541d918e823422bd82e Conclusion

      This retrospective analysis of patients with stage I NSCLCs who had received standard surgery resulted in statistically significant improvement in overall survival in patients with a low release of IL-1b in the tumor microenvironment.

      This data define a new role for IL-1β as a predictive biomarker of NSCLCs tumor behavior that can be used to better profile the use of treatments and improve patients’ outcome.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.